Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA2 | O43464 | 8/20 | 0.51 |
| ▸ | HTRA1 | Q92743 | 8/20 | 0.51 |
| ▸ | WDR5 | P61964 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766755 | 0.93 | WDR5 (0.52) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL21766758 | 0.90 | WDR5 (0.55) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL20230259 | 0.90 | WDR5 (0.59) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL26370162 | 0.90 | WDR5 (0.58) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL20230300 | 0.90 | WDR5 (0.59) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL21766753 | 0.90 | WDR5 (0.59) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL20230289 | 0.90 | WDR5 (0.55) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL21766489 | 0.89 | WDR5 (0.59) | HTRA2HTRA1WDR5ALBFOLH1 | |
| SCHEMBL21766484 | 0.89 | WDR5 (0.60) | HTRA2HTRA1WDR5ALB | |
| SCHEMBL21766492 | 0.89 | HTRA2 (0.56) | HTRA2HTRA1WDR5ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10994017-B2 | Nerve labeling compositions and uses thereof | AVELAS BIOSCIENCES, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | AVELAS ACQUISITION CORPORATION | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | GAP43, NGF, PMP22 | HTRA2 2525/4885HTRA1 4086/4885WDR5 1570/4885 |
| US-10994017-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | HTRA2 2525/4885HTRA1 4086/4885WDR5 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.